Skip to main content
OpenTrials
Completed

NCT Number: NCT07387679

Myo-inositol Versus Metformin in Patients With Polycystic Ovarian Syndrome to Treat Obesity

There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Polycystic Ovarian Syndrome Adnexal Diseases Cysts Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Neoplasms Ovarian Cysts Ovarian Diseases Polycystic Ovary Syndrome Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Bahwal Victoria Hospital

Bahawalpur, Punjab Province, 63100, Pakistan

About this study

A review of the literature reveals inconsistent outcomes of myo-inositol vs metformin in the treatment of obesity and metabolic disorders in patients with PCOS, with comparable results and myo-inositol frequently demonstrating superior tolerability and reduced gastrointestinal side effects relative to metformin. When treating obesity in women with PCOS, practicing gynecologists would be able to select more appropriate medications by gathering data from local contexts. It will lessen psychological consequences associated with obesity, such as discrimination, stigma, low self-esteem, and poor quality of life.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females aged 18-45 years
  • Diagnosed case of PCOS for more than 6 months of duration

Exclusion criteria

  • Women with hyperprolactinemia or hypothyroidism (on history & medical record review)
  • Adrenal hyperplasia or Cushing's syndrome (on history & medical record review)

Treatment and study plan

Myo-inositol

Drug

Women were given tablet myo-inositol 1 gm twice a day for 3 months.

metformin

Drug

Women received metformin 250 mg three times daily for 3 months.

Primary outcomes

  1. Reduction in body mass index

    Time frame: 3 months

    A reduction in the body mass index with respect to baseline was taken as efficacy of the treatment.

Sponsors and collaborators

Lead sponsor

Muhammad Aamir Latif

Other

Registry information

Official study title

Comparison of Myo-inositol Versus Metformin for Treating Obesity in Patients With Polycystic Ovarian Syndrome

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 4, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.